According to the positive result of SKB264 in the EGFR mutant group, a phase 3 clinical trial (NCT05870319) in patients with EGFR-mutated NSCLC has been initiated to further determine the clinical activity of SKB264. This evidence concerns the gene EGFR and non-small cell lung carcinoma.